Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database

Abstract

BackgroundDrug-induced torsades de pointes (TdP) and related clinical entities represent a current regulatory and clinical burden.ObjectiveAs part of the FP7 ARITMO (Arrhythmogenic Potential of Drugs) project, we explored the publicly available US FDA Adverse Event Reporting System (FAERS) database to detect signals of torsadogenicity for antipsychotics (APs).MethodsFour groups of events in decreasing order of drug-attributable risk were identified: (1) TdP, (2) QT-interval abnormalities, (3) ventricular fibrillation/tachycardia, and (4) sudden cardiac death. The reporting odds ratio (ROR) with 95 % confidence interval (CI) was calculated through a cumulative analysis from group 1 to 4. For groups 1+2, ROR was adjusted for age, gender, and concomitant drugs (e.g., antiarrhythmics) and stratified for AZCERT drugs, lists I and II (http://www.azcert.org, as of June 2011). A potential signal of torsadogenicity was defined if a drug met all the following criteria: (a) four or more cases in group 1+2; (b) significant ROR in group 1+2 that persists through the cumulative approach; (c) significant adjusted ROR for group 1+2 in the stratum without AZCERT drugs; (d) not included in AZCERT lists (as of June 2011).ResultsOver the 7-year period, 37 APs were reported in 4,794 cases of arrhythmia: 140 (group 1), 883 (group 2), 1,651 (group 3), and 2,120 (group 4). Based on our criteria, the following potential signals of torsadogenicity were found: amisulpride (25 cases; adjusted ROR in the stratum without AZCERT drugs = 43.94, 95 % CI 22.82–84.60), cyamemazine (11; 15.48, 6.87–34.91), and olanzapine (189; 7.74, 6.45–9.30).ConclusionsThis pharmacovigilance analysis on the FAERS found 3 potential signals of torsadogenicity for drugs previously unknown for this risk.Electronic supplementary materialThe online version of this article (doi:10.1007/s40264-013-0032-z) contains supplementary material, which is available to authorized users.

Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications

“…However, this is changing with a recent study suggesting increased risk of sudden cardiac deaths among current users of atypical antipsychotic drugs . The findings have been further corroborated by different pharmacovigilance analyses showing similar reporting ratios between typical and atypical antipsychotic medicines in clinical practice . This raises additional issues regarding the prescribing of these drugs that were previously unknown for this risk, e.g.…”

Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database

“…Since 2003, more than 7 million reports have been accumulated into FAERS, with more than 700000 records entered in 2011. In the light of its large catchment area (including also European reports potentially related to serious events) and public availability (since 2004), FAERS plays a leading role in signal detection and characterization, especially for rare events with high drug-attributable risk such as torsade de pointes (TdP) [39][40][41] . DILI shares different clinical, pharmacological and regulatory issues with TdP and, remarkably, the accuracy of FAERS to investigate DILI cases has been very recently demonstrated, especially as an important aid to systematically track emerging signals of DILI for newly marketed drug [42] .…”

Cardiovascular side effects of psychopharmacologic therapy

“…One of the most severe cardiologic AE represents a lengthening of the QT-interval, potentially leading to a ventricular arrhythmia called TdP [48]. TdP is a ventricular arrhythmia frequently connected to drug administration [49]. Drugs blamed most often are thioridazine, ziprasidone, IV haloperidol, quetiapine, amisupliride, most TCAs, SSRIs -citalopram, fluoxetine, paroxetin, and venlafaxine.…”